Mild to Moderate Asthma
Respiratory
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
AbbottABBOTT PARK, IL
1 program1
fluticasone propionate, formoterol fumaratePhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Abbottfluticasone propionate, formoterol fumarate
Celldex TherapeuticsCDX-622
Clinical Trials (2)
Total enrollment: 51 patients across 2 trials
Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma
Start: Sep 2008Est. completion: Oct 200839 patients
Phase 2Completed
A Study of CDX-622 in Participants With Mild to Moderate Asthma
Start: Feb 2026Est. completion: Mar 202712 patients
Phase 1Recruiting
Related Jobs in Respiratory
Regional Gene Therapy Consultant - Upper Midwest (IL/WI/MN)
Krystal Biotech
1h ago
$185K - $215K/yr
Regional Gene Therapy Consultant - Southwest (CO/AZ/NM/UT)
Krystal Biotech
1h ago
$185K - $215K/yr
Ausbildung zum Pharmakanten (m/w/d)
Ferring Pharmaceuticals
Kiel, Germany
Yesterday
Marketing Intern – Vertex Iberia (Spain)
Vertex Pharmaceuticals
Madrid, Spain
Yesterday
Sales Rep Neurology Region Leipzig, Halle, Gera, Jena, Weimar DE_G2M110105 - befristet bis 31.03.2027 (all genders)
Sanofi
Berlin
Yesterday
Laboratory Assistant (m/w/d)
Ferring Pharmaceuticals
Kiel, Germany
2d ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 51 patients
2 companies competing in this space